Monitoring involves imaging every 3 months, while management of adverse effects like mucositis includes good oral hygiene practices and supportive care. In an interview with Targeted Oncology TM, ...

The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO ... in accordance with the international Ki67 Working Group guidelines; and ...

This industry symposium took place during the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain, 13 th –17 th September 2024. Rolfo has received advisory board fees from ...

Despite this being a month packed with reminders to schedule your screening, the guidelines on when you should begin making mammograms a part of your annual medical checklist are incredibly unclear.

Oropharyngeal mucositis is an acute and distressing toxic effect of chemotherapy and head and neck irradiation. This oral sequela significantly impairs the daily functioning and quality of life of ...

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) Eligible patients were ...

Jaguar Health, Inc. announced that Jaguar family company Napo Pharmaceuticals (Napo) has initiated the commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the US.

Aishan Shih, RN, MS, Christine Miaskowski, RN, PhD, FAAN, Marylin J. Dodd, RN, PhD, FAAN, Nancy A. Stotts, RN, EdD, FAAN, Laurie MacPhail, PhD, DMD ...

An updated analysis from the NATALEE trial recently presented at the European Society for Medical Oncology (ESMO) Congress 2024 adds to the growing body of evidence supporting the potential of Kisqali ...